Compare Autozone Inc (AZO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Inovio Pharmaceuticals Inc — how do they compare? Autozone Inc trades at $3,020.19 (market cap $49.67B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Autozone Inc is far larger — about 632.3× Inovio Pharmaceuticals Inc's market cap, and Autozone Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AZO | INO | |
|---|---|---|
Market Cap | $49.67B | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $2.87 |
52-Week Low | $2.92K | $0.66 |
Enterprise Value | $62.05B | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,050.43, down 0.57% on the day, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 EPS of $38.07, beating expectations, but revenue growth has slowed with a net income margin of 12.4% in 2025. Analyst consensus is strongly bullish with a $3,730 price target, though recent insider selling and institutional trimming pose sentiment headwinds.
The outlook remains positive given earnings beats and international expansion, but risks include competitive pressures, margin compression, and macroeconomic sensitivity. Upside is supported by a high GF Score of 84 and DCF valuation above $3,800, yet investors should monitor execution on Q2 2026 earnings and capex efficiency.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
